The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer  by Chansky, Kari et al.
IASLC STAGING COMMITTEE ARTICLE
The International Association for the Study of Lung Cancer
Staging Project
Prognostic Factors and Pathologic TNM Stage in Surgically Managed
Non-small Cell Lung Cancer
Kari Chansky, MS,* Jean-Paul Sculier, MD, PhD,† John J. Crowley, PhD,* Dori Giroux, MS,*
Jan Van Meerbeeck, MD, PhD,‡ and Peter Goldstraw, MB, FRCS,§
on behalf of the International Staging Committee and Participating Institutions
Purpose: To assess the impact of cell type, age, and gender in
addition to pathologic tumor, node, metastasis (TNM) stage in
surgically managed stage I-IIIA non-small cell lung cancer
(NSCLC) cases from the international staging database of the
International Association for the Study of Lung Cancer.
Material and Methods: From the 67,725 cases of NSCLC submit-
ted to the staging database, 9137 surgically managed cases were
selected for which all the following variables were available: patho-
logic stage, age, gender, and specific histologic cell type. Perfor-
mance status and smoking history were examined in subsets. Meth-
ods used were Cox proportional hazards regression and recursive
partitioning and amalgamation (RPA) analyses.
Results: Pathologic TNM stage, age, and gender were all indepen-
dently prognostic for survival. The bronchioloalveolar carcinoma
(BAC) subtype had superior survival over other cell types despite
the potential for heterogeneity in this group. Adjusted comparisons
revealed a small survival advantage for squamous cell carcinomas
over non-BAC adenocarcinoma histology and also over large cell,
though the effect appeared to be limited to the male patients. RPA
revealed the importance of TNM stage primarily, and age was
prognostic within stage groups. Cell type was not found to add
prognostic value in the RPA analysis. Prognostic groups were
formed based on the RPA output, and the prognostic value of these
groupings was validated using the North American Surveillance,
Epidemiology, and End Results Registries. Performance status and
smoking history were prognostic in the subsets where data were
available. Effects of other variable were not influenced by the
inclusion of smoking status in regression models.
Conclusions: Age and gender are confirmed as important prognostic
factors in surgically resected NSCLC. Cell type is less important,
although the small population of cases classified as BAC have a
survival advantage over other histologies, and there may be a small
survival advantage for squamous cell carcinomas over non-BAC
adenocarcinomas. Imbalances between stage, gender, and cell type
at presentation may lead to a misleading result with respect to cell
type in unadjusted analyses. Pathologic TNM category is the most
important prognostic factor in this analysis.
Key Words: Non-small cell lung cancer, TNM stage, Pathologic
stage, Prognostic factors, Histology, Cell type, IASLC Lung Cancer
Staging Project.
(J Thorac Oncol. 2009;4: 792–801)
The International Association for the Study of Lung Cancer(IASLC) International Staging Committee has submitted
proposals for revision of the tumor, node, metastasis (TNM)
descriptors1–4 and stage groupings5 for lung cancer in the
forthcoming (7th) Edition of the International Union Against
Cancer and American Joint Committee on Cancer TNM
Classification of Malignant Tumors. These proposals were
developed using a very large database that was specifically
collected from individual databases for that purpose. As part
of this effort, the Prognostic Factors Subcommittee of the
International Staging Committee reported on the role of other
prognostic factors, in addition to stage, with respect to sur-
vival in 12,428 clinically staged cases of non-small cell lung
cancer (NSCLC).6 Age, gender, and performance status were
all found to be prognostic for survival after adjustment for
stage of disease. Cell type was found to be only minimally
prognostic within the non-small cell types, with the squamous
cell carcinoma cell type having a slightly superior survival
overall after adjustment for other factors. However, the effect
of cell type only appeared important in the stage IIIA cases.
Here, we examine primarily a subset of those prognos-
tic factors (cell type, age, and gender) in 9137 pathologically
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staged NSCLC surgically managed cases selected from the
IASLC database. The large number of cases and relatively
homogenous group with respect to management (surgery as
part of definitive treatment in all cases) allowed us to explore
the prognostic impact of cell type in greater detail than has
been possible in the analyses of single institution series or of
population-based registries. The relative prognoses for the ade-
nocarcinoma and squamous cell histologies have been reported
with various results. In consideration of the potential for dispro-
portionate representation of the different cell types within patient
groups, particular care was taken to explore the relationship with
respect to survival between stage, cell type, and gender.
METHODS
The methodology of the IASLC Lung Cancer Staging
Project and the major proposals have been reported.2–5,7 All
data were retrospective, and, by mutual agreement, were
transmitted to Cancer Research And Biostatistics (CRAB) as
coded data without identifiable private information, with
appropriate regulatory permission from the contributing sites.
The project was reviewed and determined to be exempt from
further human subjects review by CRAB’s institutional re-
view board.
Population
In total, 100,869 cases were submitted to the interna-
tional database, of which 81,015 remained eligible for anal-
ysis after exclusion of cases outside the study period (1990–
2000), those with unknown histology, those not newly
diagnosed at the point of entry and those with inadequate
information on stage, treatment or follow-up. Of the eligible
cases, 67,725 cases were of non-small cell histology. Of
these, 15,236 were pathologically staged, surgical cases with
sufficient T, N, and M descriptor information to reclassify
according to the IASLC proposals for the 7th edition of
TNM. From this group, 9137 stage I-IIIA cases were identi-
fied as having come from databases that distinguished the
bronchioloalveolar carcinoma (BAC) subtype from the other
adenocarcinomas as a separate category wherever it was identi-
fied and reported by the local pathologist. The time frame for
these cases mostly predates the 1999 3rd edition of WHO
guidelines for the classification of lung tumors,8 so that many
cases classified as BAC were potentially adenocarcinoma with a
BAC component, rather than pure BAC without invasion. Al-
though there was no central histopathological review of cell type
and we therefore cannot be certain that the allocation of cell type
was consistent across groups, especially in identifying BAC, the
recognition of a separate category for BAC or adenocarcinoma
with BAC features was felt to be important.
Age, gender, and cell type were available for all of
these cases. Performance status was unavailable in two thirds
of the cases; therefore, this factor was not included as a factor
in the primary analysis but was explored in a subset. Because
all of these cases were candidates for surgery, performance
status typically did not exceed 1 on the Zubrod scale in those
cases where performance status was provided. Smoking his-
tory was also unavailable for 54% of cases; therefore it was
explored separately as well. Patients who were documented
as having received neoadjuvant chemotherapy were not in-
cluded in these analyses. Cases with notation of chemother-
apy at some time point after surgery (in about 8.5% of the
cases where the data were provided) were allowed.
Cases included in the primary analysis were from 27
separate databases representing 18 countries. The largest
contributions were from the Bronchogenic Carcinoma Co-
operative Group of the Spanish Society of Pneumology and
Thoracic Surgery (GCCB-S, 1851 cases) and the Norway
Registry (1737 cases), which collected surgical cases specif-
ically. The majority of cases were from surgical series or
hospital consortia submitting surgical cases to a central reg-
istry. A small proportion of cases (143 cases) were from
population-based registries (collecting cases from all treat-
ment modalities) and 476 were from clinical trials (Table 1).
Of the 9137 cases included in this analysis, 1950 had also been
included in the previous analysis of clinically staged cases.
Statistical Analysis
Survival was measured from the date of surgery until
death due to any cause, and median survival was calculated
by the Kaplan-Meier method. Prognostic groups were as-
sessed by Cox regression analysis on overall survival, using
the SAS system for windows version 9.0 PHREG procedure.
In regression analyses, stage and histology categories were
modeled categorically using indicator variables. For ease of
interpretation, age was considered as a dichotomous categor-
ical variable with a cutpoint of 70. Although the cutpoint for
age was 75 in the previous paper from this group, there was
a smaller proportion of cases that were over age 75 in the
current surgical subset. Thus, a cutpoint of 70 was chosen,
which is consistent with the age cutpoint frequently cited for
clinical trials in “elderly” patients. The decision to use a
dichotomous age variable was reinforced by the fact that
when regression models were adjusted by age as a continuous
variable for comparison, the resulting hazard ratios for cell
type, stage, and gender were the same to within 0.03.
Significance testing for binary variables (age and gender) was
done using the Wald statistic. Comparisons of individual
levels of stage and histology also used a Wald test for each
individual hypothesis. Because of the number of variables
used and models considered, the threshold for statistical
significance was adjusted to 0.01.
Recursive partitioning and amalgamation (RPA) anal-
yses9 were performed to generate tree-based models by stage
(proposed version 7 TNM) plus the key prognostic factors:
age, gender, and cell type. The tree algorithms were per-
TABLE 1. Geographical Representation of Submission
Types
Total
Cases
Clinical
Trial Consortium Registrya Series
Asia 1135 0 0 0 1135
Australia 1383 0 0 0 1383
Europe 4818 10 1851 1880 1077
North America 1801 466 0 0 1335
All regions 9137 476 1851 1880 4930
a Category includes surgical registry and population-based registry.
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formed on a training set consisting of the entire set of 9137
cases available for analysis, and the resultant prognostic
groupings were then tested for validation against appropriate
surgical cases in the 1998–2002 time frame from the U.S.
National Cancer Institute’s Surveillance, Epidemiology, and
End Results Registries (SEER) database. To ensure a com-
parable study group for validation, only those NSCLC cases
in the appropriate TNM category and with a surgery code
indicating a surgical resection were selected. SEER reports
best stage, which is generally pathologic stage in a surgically
resected case.10 TNM stage categories were derived from
extent of disease codes (such as tumor size and other tumor
descriptors) and N-stage, which are sufficient to reclassify
cases to the revised staging scheme. Only cases that were
reclassified as stage I-IIIA in the proposed new staging
scheme were selected.
Variables entered into the RPA analysis were stage (as
an ordered variable), age (as both categorical and continuous
in separate iterations), gender, and cell type (as a group of
indicator variables). The RPA generated tree-based models for
the survival data used logrank test statistics for selecting “best
splits” of the data to form the terminal groupings and bootstrap
resampling to correct for the adaptive nature of the splitting
algorithm. For validation of the survival tree result, the terminal
nodes were then grouped according to similar hazards and the
newly formed groups were evaluated using the SEER database.
RESULTS
The adenocarcinoma and squamous cell carcinoma his-
tologies comprised the largest proportions of the study sam-
ple (36 and 49%, respectively). Squamous cell carcinomas
predominated in stages II and III and were less frequently
stage I (35%) as compared with the adenocarcinomas (46%).
There were imbalances with respect to gender and histology.
Among female patients, 55% were adenocarcinoma and 25%
squamous cell. In contrast, the male patients were 30%
adenocarcinoma and 57% squamous cell (Table 2).
Survival is ordered according to pathologic TNM cat-
egory (proposed version 7) as expected (Figure 1A), with
median survival estimates ranging from 19 months for stage
IIIA to 95 months for stage IA. For cell type across all stages
combined, the BAC subtype has a median survival of 83
months, followed by adenocarcinoma, 45 months, versus 44
months for squamous cell carcinomas, 34 months for large
cell, and 26 months for adenosquamous (Figure 1B).
The following variables were considered in Cox pro-
portional hazards regression analyses: pathologic TNM stage
(using IASLC proposals for the 7th edition of TNM), age,
gender, and histologic cell type (adenocarcinoma versus
squamous cell carcinoma versus large cell versus adenosqua-
mous versus BAC). Unadjusted analyses (where each factor
was considered independently) revealed significant differ-
ences between BAC and all other cell types, between male
and female patients, and between patients 70 and older versus
patients less than 70 years of age (Table 3, results for
unadjusted models). In unadjusted analyses across all stages
and both genders, the adenocarcinomas and squamous cell
carcinomas did not have a significantly different prognosis.
However, in a model including all factors, (cell type, patho-
logic stage, gender, and age), squamous cell has a significant
survival advantage over adenocarcima and large cell, sug-
gesting that, all other things being equal, the squamous cell
carcinoma histology carries a slightly better prognosis (Table
3, results for adjusted models). There was no significant
difference between large cell and adenocarcinoma, or be-
tween adenosquamous and any other non-BAC histology.
There is a small but statistically significant interaction
between histology and gender (p  0.006 on a global test
comparing full and reduced models). To illustrate the nature
of the interaction, the survival statistics for histology, age,
and stage are shown separately for female and male patients
in Table 3. In female patients, there is no significant differ-
ence between squamous cell carcinomas and adenocarcino-
mas or between any other non-BAC histologies after adjust-
TABLE 2. Distribution of Cell Type Across Gender and Stage Categories for the Pathologically
Staged I-IIIA (IASLC Proposals for 7th ed TNM) Database, N  9137
BAC Adenocarcinoma Squamous Cell Large Cell Adenosquamous Total
Females
Stage I 183 (16%) 648 (56%) 247 (21%) 61 (5%) 10 (1%) 1149
Stage II 59 (8%) 363 (51%) 219 (31%) 64 (9%) 11 (2%) 716
Stage III 34 (7%) 270 (57%) 117 (25%) 37 (8%) 18 (4%) 476
All females 276 (12%) 1281 (55%) 583 (25%) 162 (7%) 39 (2%) 2341
Males
Stage I 154 (6%) 892 (35%) 1296 (51%) 175 (7%) 19 (1%) 2536
Stage II 59 (2%) 683 (27%) 1572 (61%) 189 (7%) 58 (2%) 2561
Stage III 28 (2%) 479 (28%) 1012 (60%) 124 (7%) 56 (3%) 1699
All males 241 (4%) 2054 (30%) 3880 (57%) 488 (7%) 133 (2%) 6796
Female  male
Stage I 337 (9%) 1540 (42%) 1543 (42%) 236 (6%) 29 (1%) 3685
Stage II 118 (4%) 1046 (32%) 1791 (55%) 253 (8%) 69 (2%) 3277
Stage III 62 (3%) 749 (34%) 1129 (52%) 161 (7%) 74 (3%) 2175
All patients 517 (6%) 3335 (36%) 4463 (49%) 650 (7%) 172 (2%) 9137
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ing for stage and other factors (though the survival estimates
favor the adenocarcinomas). There is, however, a significant
survival advantage for squamous cell carcinoma over adeno-
carcinoma and large cell among male patients, and this seems
to be the source for the finding that there is a small survival
advantage for squamous cell carcinomas overall.
Within stage groups, no differences were seen between
any of the non-BAC histologies that reached the significance
threshold of 0.01, though the hazard ratios in the stage II and
III categories favored the squamous cell cases, and BAC had
a significant survival advantage (p  0.0001) among the
stage I cases only (statistics not shown).
Stage, age, gender, and cell type were entered into a
RPA analysis to generate a survival tree of recursive splits on
the dataset. Viewing only the splits that were statistically
significant after accounting for multiple tests, stage, age, and
(in a limited partition of the data) gender remained as impor-
tant variables (Figure 2). Unlike the results of a regression
analysis, the survival tree resulting from an RPA method can
often provide an easy visualization of the relative importance
of various factors in particular subsets of the data.
The most important factor overall is pTNM stage, and
within stage categories, age is prognostic. Beyond that, in the
under-70 stage IA group, female gender is a favorable prog-
nostic factor. Using this recursive splitting algorithm, there
was never a point at which cell type was found to be the most
important factor in any partition of the data. Entering age as
a continuous rather than categorical variable did not change
the structure of the tree with respect to the relative importance
and position of the factors involved in the splits, so a
categorical representation (with a cutpoint at 70 years) was
chosen. The RPA resulted in a survival tree with 10 terminal
nodes that could be grouped according to hazard ratios to
form five groups of approximately similar prognosis. Groups
could be defined according to the following criteria:
Stage IIIA—group 5.
Stage IIB—group 4, increase by one level (to group 5) if age70.
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FIGURE 1. Survival according to A,
pathologic stage (IASLC proposals
for 7th Ed.) and B, cell type. ADCA,
adenocarcinoma; ADSQ, adenosqua-
mous; BAC, bronchioloalveolar;
LARGE, large cell; SQUAM, squa-
mous cell.
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Stage IIA—group 3, increase by one level if age 70.
Stage IB—group 2, increase by one level if age 70.
Stage IA Males—group 2, increase by one level if age 70
Stage IA Females—group 1, increase by 2 levels (to group 3)
if age 70.
For example, a stage IIA patient, age 80, would be
placed in group 4. A stage IA patient, age 65, would be
placed in group 2 if male, or group 1 if female.
Applying these definitions to the SEER data (n 9221)
for validation resulted in the survival curves seen in Figure 3.
All adjacent groups are significantly different from each other
at the 0.0001 level, with hazard ratios between adjacent
groups ranging from 1.34 to 1.75. Adding cell type as a set of
indicator variables to a regression model containing the RPA
group variable was a significant addition by a global test,
largely because of differences between squamous cells, ade-
nocarcinomas, and BAC. However, it should be noted that
this addition only improved the R2 value (a measure of
percent variance explained11) from 21.8 to 22.6.
In the 3027 cases where performance status data were
available, performance status was independently prognostic
for survival in an analysis adjusting for gender, stage, and cell
type. Using the Zubrod scale, a performance status of 1
conferred a poorer prognosis than a performance status of 0
(H.R. 1.16, p 0.005), and the small number of cases (n
35) with a performance status of two or higher had a worse
prognosis than those with performance status 1 (H.R. 
1.61). Importantly, in this analysis of a subset of the data, the
findings for the different cell types, gender, age, and stage
remained the same as those resulting from the entire dataset
where performance status was not included. This suggests
that the findings for these factors are independent of perfor-
mance status.
Smoking history was examined in the subset where the
data were available to distinguish between current (n 
1258), former (n  1155), and never-smokers (n  54).
Smoking status differed by cell type, so that 1.3% of squa-
mous cell cases were never-smokers, when compared with
9.4% of adenocarcinomas and 20% of BAC. In this subset,
there was no difference between former smokers versus
never-smokers (H.R.  1.16, p  0.16), but current smokers
had a worse prognosis than former smokers (H.R.  1.21,
p 0.0001) and also worse than never-smokers (H.R.1.41,
p  0.0017). Definitions for “former smoker” may have
varied, but it could be concluded that smoking conferred a
negative prognosis in a univariate setting. In a multivariate
analysis including stage, cell type, gender, and age, the
difference between current and former smokers remained
significant (p  0.001), although the difference between
former and never-smokers did not (p 0.93). The addition of
smoking status as a factor in the model did not modify the
observed effects of other factors.
DISCUSSION
Previous analyses of prognostic factors in surgically
resected NSCLC have covered specific areas such as smoking
TABLE 3. Survival Statistics and Comparisons from Univariate and Multivariate Cox Proportional Hazards Regression Models
for all Patients, and for Females and Males Separately
Factor
Overall Survival
Median (mo)a/1
yr/5 yr All Patients Comparison
Unadjusted H.R.b
All Patients
Adjusted H.R.c
All Patients Females Males
Cell type
BAC 83/92%/61%
Adenocarcinoma 45/82%/44% Adeno vs. BAC 1.56 (p  0.0001) 1.35 (p  0.0001) 1.42 (p  0.0009) 1.25 (p  0.02)
Squamous cell 44/79%/43% Squam vs. Adeno 1.03 (p  0.291) 0.86 (p  0.0001) 1.02 (p  0.80) 0.83 (p  0.0001)
Large cell 34/72%/41% Large vs. Squam 1.13 (p  0.023) 1.19 (p  0.0009) 1.09 (p  0.45) 1.19 (p  0.0032)
Adenosquamous 26/73%/29% AdSq vs. Large 1.23 (p  0.046) 0.98 (p  0.846) 1.21 (p  p  0.38) 0.94 (p  0.60)
Gender
Female 66/85%/52%
Male 40/79%/41% Male vs. female 1.32 (p  0.0001) 1.21 (p  0.0001) N/A N/A
Age
70 49/81%/46%
70 38/78%/38% Age 70 vs. 70 1.28 (p  0.0001) 1.51 (p  0.0001) 1.47 (p  0.0001) 1.52 .0001
TNM categoryd
IA 95/93%/66%
IB 75/89%/56% IB vs. IA 1.33 (p  0.0001) 1.30 (p  0.0001) 1.39 (p  0.0007) 1.25 (p  0.0002)
IIA 44/82%/43% IIA vs. IB 1.39 (p  0.0001) 1.44 (p  0.0001) 1.48 (p  0.0001) 1.44 (p  0.0001)
IIB 29/74%/35% IIB vs. IIA 1.28 (p  0.0001) 1.30 (p  0.0001) 1.43 (p  0.0003) 1.27 (p  0.0001)
IIIA 19/65%/23% IIIA vs. IIB 1.44 (p  0.0001) 1.46 (p  0.0001) 1.44 (p  0.0001) 1.46 (p  0.0001)
Factors included were cell type, gender, age, and pathologic stage (according to proposed UICC/AJCC Version 7). All patients N 9137; Females: N 2341; Males: N 6796.
a Median overall survival from Kaplan-Meier estimate.
b Hazard ratio and p-value from Cox proportional hazards regression analysis for the factors histology (by indicator variables), gender, age, and stage (by indicators), modeled separately.
c Hazard Ratio and p-value from a multivariate Cox proportional hazards regression model containing histology, gender (female as referent), age (70 as referent), and stage (indicator).
d TNM category proposed version 7.
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history,12,13 comorbidities,14,15 and general clinical and de-
mographic features,12,16–22 with the typical number of cases
ranging from less than 100 to approximately 5000. Other
studies have had sample sizes ranging from 1000 to 19,000
and may have an impressive list of covariates to study but do
not focus exclusively on surgically managed patients.23–27 A
systematic review of the literature in 2002 revealed that the
number of factors studied overall is narrow, and the results
heterogeneous.28
Studies of gene expression11,29–33 show promise espe-
cially as a means to identify early-stage patients who (by
virtue of a poor prognosis or a predictive marker) might
benefit from adjuvant therapy. However, these studies usually
involve a small number of patients, often from a range of
treatment modalities. Gene expression profiling studies in
lung cancer are (with some exceptions31–33) limited with
respect to cell type, and the prognostic capabilities of newly
discovered profiles are rarely tested in conjunction with other
prognostic factors. Gene signatures will only be applicable in
the clinical setting when they can be consistently proven to
provide information beyond that which can be derived from
readily available clinical and anatomic factors.34 Until then, in
lung cancer we rely primarily on stage category, certain emerg-
ing biologic markers,35 and clinical patient characteristics.
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FIGURE 2. Survival tree output from
recursive partitioning and amalgam-
ation analysis. Upper number at each
node is the log hazard ratio with the
leftmost group as referent. Lower
number is the number of cases
present in each category. Groups with
similar hazards are consolidated with
colored circles. Cell types were in-
cluded in the analysis, but do not
seem in the survival tree output as
none satisfied the selection process for
important split points at any point in
the algorithm.
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FIGURE 3. Validation of prognostic
groups as defined by RPA, SEER data,
n  9221. Groups are defined in the text
and shown by color in the consolidated
terminal nodes of the survival tree shown
in Figure 2.
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The methods used in the current analyses are meant to
be complementary. Recursive partitioning analyses (RPA)
have been used to develop prognostic categories to inform the
development of staging systems, for example in lung cancer
as part of the IASLC effort5 and in multiple myeloma.36 This
type of application presumes that patients will, in practice, be
allotted to the categories that were generated by the RPA
results to provide an estimate of prognosis. However, tree-
based models such as RPA are often used as part of explor-
atory analyses, to gain understanding without the intention of
applying the terminal groupings to clinical practice. They
may be used instead, for example, to create prognostic cate-
gories within which to analyze the effect of a certain treat-
ment variable,37 or to suggest further refinement to existing
classification schemes.38 The hierarchical structure of RPA
modeling can elucidate relationships between factors that are
not easily seen with traditional regression models, allowing
for the detection of relationships based on conditional infor-
mation in specific subsets of the cases. In the context of this
study, the survival tree provides a visualization of the most
important factors and the subsets within which they are most
important. The amalgamation of the terminal nodes into
groups facilitates validation of the results, but in this case
there is no intent to apply these groups to clinical practice.
In this analysis of surgical NSCLC cases from the
IASLC lung cancer staging project, age, stage category, and
gender were all prognostic for survival. Cases designated as
BAC had a superior prognosis compared with other histolo-
gies, and squamous cell carcinomas were slightly favored
over adenocarcinomas and large cell, but only after adjusting
for imbalances in gender and stage. The superior prognosis
for the squamous cell carcinomas when compared with other
histologies was not seen in female patients.
In a subset of the dataset with sufficient information,
former smokers had a better prognosis than current smokers,
and the small number of never-smokers likely hindered our
ability to draw a reliable conclusion about that category. Most
studies report a survival advantage for nonsmokers or lighter
smokers,12,13,39 although some report that adjusting for his-
tology or other factors eliminates the significance of smoking
status.15,40 Adjusting for smoking status did not modify the
effects of cell type or other factors. This finding suggests that
results based on gender, stage, and cell type are valid even in
the absence of a smoking history. However, smoking and cell
type are clearly not independent, with the majority of non-
smokers shown to be in the adenocarcinoma (especially
BAC) categories in this and other studies,12,40–42 and both
factors are also related to gender. The interactions among
these factors are important in NSCLC research, and the
acquisition of smoking status should be included in the data
collection process for future investigations. The importance
of this factor will increase as newer data collections will be
more likely to be linked with laboratory data on various
molecular markers. Analyses sometimes focus on smoking
intensity (by means of pack-years or other measures)12,39
rather than the “ever-smoked” versus “never-smoked” cate-
gories because of inadequate numbers of nonsmoking lung
cancer patients for study. However, the distinction between
ever-smokers and never-smokers will be important, and studies
should be designed to recruit as many never-smokers as possi-
ble. Performance status was also prognostic in the subset where
data were available, and this too is an important factor that
should not be ignored when collecting data on surgical cases.
Although gender and stage are almost universally rec-
ognized as prognostic factors in lung cancer, reports vary
regarding the impact of histology, and particularly regarding
comparisons between the two most common non-small cell
histologies, where results have been inconsistent. Much of the
disparity could potentially be explained by the omission of
other important factors in such analyses.
Some examples of recent findings are given in Table 4,
showing various results for survival comparisons by histol-
ogy. Within cases of resectable NSCLC, failure to adjust for
stage and gender is the common feature in studies where the
adenocarcinoma cell type is found to be superior. For exam-
ple, the recent publication from the Japanese Joint Committee
of Lung Cancer Registry16 reported on an impressively large
collection of over 13,000 lung cancer cases that underwent
surgery at participating hospitals during a 1-year period in
2002. In addition to reporting superior survival for female
patients, the adenocarcinoma cell type was also found to
carry a better prognosis overall, with a 67% 5-year survival
for adenocarcinoma, compared with 53% for the squamous
cell type. The authors acknowledged that the analyses of
prognostic factors (including histology) were not adjusted for
other factors such as stage or gender. Such adjustment may
have led to a different result.
The authors also noted that BAC and adenocarcinoma
with BAC were not identified separately but were included in
the adenocarcinoma category. This is reasonable given that
the BAC subclassification has undergone several changes in
definition, with new recommendations from a joint effort of
the IASLC, ERS, and ATS forthcoming. In any case, a BAC
designation by any criteria seems to confer a more favorable
prognosis,8 and so the inclusion of BAC with the other
adenocarcinomas may boost the survival prognosis for the
adenocarcinoma category overall.17 Conversely, the identifi-
cation of BAC as a category distinct from other adenocarci-
nomas may reveal a survival advantage for squamous cell
carcinoma relative to non-BAC adenocarcinoma.18
Studies that adjusted for stage (with or without gender)
found either no difference between adenocarcinoma and
squamous cell, or a superior prognosis for squamous cell. For
studies that reported results from unadjusted along with
results from adjusted analyses, the unadjusted analyses typi-
cally found in favor of adenocarcinoma, whereas the adjusted
analyses found no difference (Table 4).
In this study, there are clear imbalances between stage
and cell type and gender and cell type. The squamous cell
cases are only 13% female, versus 38% female for the
adenocarcinomas. With regard to stage, 46% of the adeno-
carcinoma cases were stage I, compared with just 35% for the
squamous cell carcinomas. Although none of the contributing
databases drew explicitly from a CT screening program, the
large registries and consortia would not have excluded such
cases. It is possible that some of the stage I cases were
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screen-detected, and among adenocarcinomas the screen-
detected cases seem to have a much longer tumor volume
doubling time.43 Furthermore, given that the IASLC database
derives from multiple sources, some BAC cases or cases of
adenocarcinoma with BAC features are certain to have re-
mained unidentified within the larger adenocarcinoma cate-
gory, with the majority of those most likely being female
patients with early stage disease. Adjusting for stage and
gender mitigates any effect of imbalance that would favor the
adenocarcinoma cell type, and reveals a possible survival
advantage for the squamous cell type. Cell type will continue
to be an important factor for data collection, especially in
clinical trials, as studies of newer agents may show different
effects depending upon histology.44,45
Using the database of the IASLC International Staging
Project, we conclude that for surgically managed pathologi-
cally staged I-IIIA NSCLC (according to the IASLC propos-
als for the 7th edition of TNM), age, gender, and to a lesser
degree certain cell types, in addition to pTNM stage are all
prognostic. Stage remains to be the most important factor,
followed by age, and in early stage cases, gender. The cases
classified as BAC in this dataset would have varied from pure
noninvasive BAC to invasive adenocarcinoma with BAC
components. Nevertheless, this category had a prognosis
distinct from the other subtypes. Regarding a comparison
of the two most common NSCLC lung cancer histologies,
the squamous cell carcinomas may have a better prognosis
than the non-BAC adenocarcinomas, particularly among
male patients with early stage disease, but the question
remains as to whether the undetected inclusion of the BAC
subtype within the adenocarcinomas obscures what might
otherwise be a survival advantage for squamous cells in
female and male patients. Data collection for future studies
should uniformly require smoking history in addition to
the other factors.
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et al.21
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ogy Group (RTOG), USA; R. Damhuis, Rotterdam Cancer
Registry, The Netherlands; R. Komaki and P. K. Allen, MD
Anderson Cancer Center-Radiation Therapy (MDACC-RT),
Houston, Texas; J. P. Sculier and M. Paesmans, European
Lung Cancer Working Party (ELCWP); Y. L. Wu, Guang-
dong Provincial People’s Hospital, Peoples Republic of China;
M. Pesek and H. Krosnarova, Faculty Hospital Plzen, Czech
Republic; T. Le Chevalier and A. Dunant, International Ad-
juvant Lung Cancer Trial (IALT), France; B. McCaughan and
C. Kennedy, University of Sydney, Sydney, Australia; F.
Shepherd and M. Whitehead, National Cancer Institute of
Canada (NCIC); J. Jassem and W. Ryzman, Medical Univer-
sity of Gdansk, Poland; G. V. Scagliotti and P. Borasio,
Universita’ Degli Studi di Torino, S Luigi Hospital, Orbas-
sano, Italy; K. M. Fong and L. Passmore, Prince Charles
Hospital, Brisbane, Australia; V. W. Rusch and B. J. Park,
Memorial Sloan-Kettering Cancer Center, New York, USA;
H. J. Baek, Korea Cancer Centre Hospital, Seoul, South
Korea; R. P. Perng, Taiwan Lung Cancer Society, Taiwan;
R. C. Yung, A. Gramatikova, John Hopkins University, USA;
J. Vansteenkiste, Leuven Lung Cancer Group (LLCG), Bel-
gium; C. Brambilla and M. Colonna, Grenoble University
Hospital-Isere Cancer Registry, France; J. Hunt and A. Park,
Western Hospital, Melbourne Australia; J. P. Sculier and T.
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